Decision

Early access to medicines scheme (EAMS) scientific opinion: Atezolizumab for locally advanced or metastatic urothelial carcinoma

EAMS scientific opinion given to Atezolizumab to treat locally advanced or metastatic urothelial carcinoma, including the public assessment report.